VitiPure portfolio targets pharmacopoeia-grade, low-endotoxin and stability-critical applications, while US facility ...

The acquisition, approved at the Board meeting held on September 13, 2026, is intended to streamline company’s corporate ...

Post-transaction, the combined stake held by the Promoter and Promoter Group in Granules India fell from 38.02% to 31.08% of ...

Encoded Therapeutics, a clinical-stage biotechnology company, has raised $275 million in Series F financing, providing the ...

The inspection was conducted over five days at the API manufacturing unit located in the Industrial Development Area, ...

The winners were announced at the finale held in Bengaluru, in the presence of Kiran Mazumdar-Shaw, Executive Chairperson, ...

For India, the opportunity is to combine technological capability with public-health experience, clinical expertise and ...

These themes formed the backdrop to the Healthcare Businesswomen’s Association (HBA) India’s third India Leadership Summit ...

The Swiss affordable-medicines giant said its new Bio100 strategy will put biosimilars at the heart of its long-term ...

The unannounced onsite USFDA bioequivalence inspection was conducted from 31st August, 2026 to 10th September, 2026 ...

Image Credits: Bhushan Malpure/LinkedIn. Bhushan Malpure has been elevated to Head of Marketing at Cipla, marking another step in his pharmaceutical marketing career with the company. Malpure has held ...

Rs 350 crore—will go toward a new, fully backward-integrated Ibuprofen manufacturing unit at IOLCP’s Barnala, Punjab facility ...